CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 2009; 59:303-313
doi: 10.3322/caac.20029
© 2009 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
 New Molecular Classifications of Breast Cancer
Right arrow FREE NURSING CONTACT HOURS
Right arrow Submit a letter to the editor
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Cianfrocca, M.
Right arrow Articles by Gradishar, W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cianfrocca, M.
Right arrow Articles by Gradishar, W.

New Molecular Classifications of Breast Cancer

Mary Cianfrocca, DO1 and William Gradishar, MD2

1Assistant Professor, Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
2Professor, Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

Corresponding author: Mary Cianfrocca, DO, Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair, Suite 850, Chicago, IL 60611; m-cianfrocca{at}northwestern.edu

To earn free CME credit or nursing contact hours for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org.

DISCLOSURES: Dr. Cianfrocca has received honoraria from Genomic Health and Genentech. No other conflict of interest relevant to this article was reported.

Traditionally, pathologic determinations of tumor size, lymph node status, endocrine receptor status, and human epidermal growth factor receptor 2 (HER2) status have driven prognostic predictions and adjuvant therapy recommendations for patients with early stage breast cancer. However, these prognostic and predictive factors are relatively crude measures, resulting in many patients being overtreated or undertreated. As a result of gene expression assays, there is growing recognition that breast cancer is a molecularly heterogeneous disease. Evidence from gene expression microarrays suggests the presence of multiple molecular subtypes of breast cancer. The recent commercial availability of gene expression profiling techniques that predict risk of disease recurrence as well as potential chemotherapy benefit have shown promise in refining clinical decision making. These techniques will be reviewed in this article. CA Cancer J Clin 2009;59:303–313. © 2009 American Cancer Society, Inc.




eLetters:

Read all eLetters

eLetter to "New Molecular Classifications of Breast Cancer"
Yufeng Dou, et al.
CA Online, 29 Oct 2009 [Full text]
Concerns about the optimal use of gene expression profiling technique
Shaowei Liu, et al.
CA Online, 29 Oct 2009 [Full text]
Molecular Classifications of Breast Cancer Clinical Applications, the Premature Period
Jiyuan Sun, et al.
CA Online, 2 Nov 2009 [Full text]
The gene expression assay: a fascinating technique that needs further exploration
Yong-Gang Lv, et al.
CA Online, 10 Nov 2009 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by American Cancer Society.